RPMI, Roswell park memorial institute

  • 文章类型: Journal Article
    UNASSIGNED:使用年龄相关性黄斑变性(AMD)患者的脂蛋白颗粒组成和大小以及载脂蛋白指标的核磁共振定量测量,研究血清胆固醇流出能力(血清接受胆固醇的能力)及其调节因素。
    未经评估:病例对照研究。
    未经评估:80例早期AMD(eAMD)患者的四百二份血清样本,和212名新生血管性AMD(nAMD)患者,包括80例典型nAMD(tAMD)和132例息肉状脉络膜血管病变(PCV),和110名年龄和性别匹配的对照参与者。
    UNASSIGNED:参与者的血清显示使用体外细胞测定法测量的胆固醇流出能力和使用核磁共振测量的脂蛋白亚组分(南丁格尔,有限公司)。在患者和对照参与者中研究了胆固醇流出能力(以百分比衡量)与脂质亚组分之间的关联。
    未经证实:对照组的胆固醇外排能力和脂质亚组分,eAMD,和nAMD。HDL亚组分与胆固醇流出能力之间的关联。
    UNASSIGNED:调整年龄后,eAMD患者(68.0±11.3%[平均值±标准偏差])和nAMD患者(75.9±27.7%)的胆固醇外排能力高于对照组(56.9±16.7%),性别,并使用降脂药(P<0.0001)。核磁共振脂质组学显示,eAMD(9.96±0.27mm[平均值±标准偏差])和PCV(9.97±0.23mm)的HDL平均直径均大于对照组(9.84±0.24mm;两者P=0.0001)。在28个HDL亚组分中,大部分的小,中等,和大型HDLs,但是7个超大的HDLs没有一个,与eAMD和PCV的胆固醇流出能力中度相关(R=0.149-0.277)。
    未经证实:eAMD和PCV的血清胆固醇流出能力增加,但不是tAMD,可能反映了tAMD和PCV中脂质失调的潜在病理生理学特征的差异。进一步的研究应针对研究HDL在AMD中的多种生物学活性,包括黄斑色素运输,炎症的调节,和局部胆固醇运输系统。
    UNASSIGNED: To investigate serum cholesterol efflux capacity (the ability of the serum to accept cholesterol) and factors that regulate it using nuclear magnetic resonance-quantified measures of lipoprotein particle composition and size and apolipoproteins metrics in patients with age-related macular degeneration (AMD).
    UNASSIGNED: Case-control study.
    UNASSIGNED: Four hundred two serum samples from 80 patients with early AMD (eAMD), and 212 patients with neovascular AMD (nAMD), including 80 with typical nAMD (tAMD) and 132 with polypoidal choroidal vasculopathy (PCV), and 110 age- and gender matched control participants.
    UNASSIGNED: Serum from participants showed cholesterol efflux capacity measured using in vitro cell assays and lipoprotein subfractions measured using nuclear magnetic resonance (Nightingale, Ltd). Associations between cholesterol efflux capacity (measured in percentage) and lipid subfractions were investigated in the patients and control participants.
    UNASSIGNED: Cholesterol efflux capacity and lipid subfractions in control, eAMD, and nAMD. Associations between HDL subfractions and cholesterol efflux capacity.
    UNASSIGNED: Cholesterol efflux capacity was higher in patients with eAMD (68.0 ± 11.3% [mean ± standard deviation]) and nAMD (75.9 ± 27.7%) than in the control participants (56.9 ± 16.7%) after adjusting for age, gender, and use of lipid-lowering drug (P < 0.0001). Nuclear magnetic resonance lipidomics demonstrated that the mean diameter of HDL was larger both in eAMD (9.96 ± 0.27 mm [mean ± standard deviation]) and PCV (9.97 ± 0.23 mm) compared with that of the control participants (9.84 ± 0.24 mm; P = 0.0001 for both). Among the 28 HDL subfractions, most of the small, medium, and large HDLs, but none of the 7 extra large HDLs fractions, were associated moderately with cholesterol efflux capacity in eAMD and PCV (R = 0.149-0.277).
    UNASSIGNED: Serum cholesterol efflux capacity was increased in eAMD and PCV, but not tAMD, possibly reflecting differential underlying pathophysiologic features of lipid dysregulation in tAMD and PCV. Further studies should be directed toward investigating the diverse biological activities of HDL in AMD, including macular pigment transport, regulation of inflammation, and local cholesterol transport system.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    新薄荷醇,一种环状单萜,是薄荷醇的立体异构体,存在于薄荷醇的精油中。它在食品中用作调味剂,在化妆品和药品,因为它的冷却效果。然而,新薄荷脑对其抗癌潜力的研究并不多。此外,靶向透明质酸酶,组织蛋白酶-D,植物化学物质和ODC是癌症预防和/或治疗的有效方法之一。
    研究新薄荷脑对人类癌症的分子和细胞靶标的抗增殖潜力(A431,PC-3,K562,A549,FaDu,MDA-MB-231,COLO-205,MCF-7和WRL-68)和正常(HEK-293)细胞系。
    使用SRB在人类癌症和正常细胞系上评估了新薄荷脑的效力,NRU和MTT测定。在无细胞和基于细胞的测试系统中进行了新薄荷醇的基于分子靶标的研究。Further,通过实时定量PCR分析和分子对接研究证实了新薄荷脑的效力.在小鼠EAC模型上进行了新薄荷脑的体内抗癌潜力,并通过计算机模拟进行了毒性检查。离体和体内方法。
    新薄荷醇通过阻止G2/M期并增加亚二倍体细胞的数量,对人表皮样癌(A431)细胞具有有希望的活性(IC5017.3±6.49μM)。它显着抑制透明质酸酶活性(IC5012.81±0.01μM)并影响微管蛋白聚合。表达分析和分子对接研究支持基于体外分子和细胞靶标的结果。新薄荷醇在75mg/kgbw时可预防EAC肿瘤形成58.84%,并抑制透明质酸酶活性高达10%,腹膜内剂量。在急性口服毒性研究中发现1000毫克/千克体重的口服剂量是安全的。
    新薄荷醇通过抑制微管蛋白聚合和透明质酸酶活性来延缓皮肤癌细胞的生长,负责肿瘤的生长,转移,和血管生成。
    Neomenthol, a cyclic monoterpenoid, is a stereoisomer of menthol present in the essential oil of Mentha spp. It is used in food as a flavoring agent, in cosmetics and medicines because of its cooling effects. However, neomenthol has not been much explored for its anticancer potential. Additionally, targeting hyaluronidase, Cathepsin-D, and ODC by phytochemicals is amongst the efficient approach for cancer prevention and/or treatment.
    To investigate the molecular and cell target-based antiproliferative potential of neomenthol on human cancer (A431, PC-3, K562, A549, FaDu, MDA-MB-231, COLO-205, MCF-7, and WRL-68) and normal (HEK-293) cell lines.
    The potency of neomenthol was evaluated on human cancer and normal cell line using SRB, NRU and MTT assays. The molecular target based study of neomenthol was carried out in cell-free and cell-based test systems. Further, the potency of neomenthol was confirmed by quantitative real-time PCR analysis and molecular docking studies. The in vivo anticancer potential of neomenthol was performed on mice EAC model and the toxicity examination was accomplished through in silico, ex vivo and in vivo approaches.
    Neomenthol exhibits a promising activity (IC50 17.3 ± 6.49 μM) against human epidermoid carcinoma (A431) cells by arresting the G2/M phase and increasing the number of sub-diploid cells. It significantly inhibits hyaluronidase activity (IC50 12.81 ± 0.01 μM) and affects the tubulin polymerization. The expression analysis and molecular docking studies support the in vitro molecular and cell target based results. Neomenthol prevents EAC tumor formation by 58.84% and inhibits hyaluronidase activity up to 10% at 75 mg/kg bw, i.p. dose. The oral dose of 1000 mg/kg bw was found safe in acute oral toxicity studies.
    Neomenthol delayed the growth of skin carcinoma cells by inhibiting the tubulin polymerization and hyaluronidase activity, which are responsible for tumor growth, metastasis, and angiogenesis.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    新城疫病毒(NDV)溶胞产物已被确定为用于肿瘤治疗的独特且有效的免疫刺激根。因此,本研究的目的是研究NDV溶胞产物瘤内给药对人乳头瘤病毒(HPV)相关的TC-1同源癌细胞移植的C57BL/6小鼠模型的免疫反应和肿瘤消退的影响。为了进一步研究抗肿瘤反应的潜在机制,使用乳酸脱氢酶(LDH)释放和MTT测定法测量脾细胞中的细胞溶解和淋巴细胞增殖反应,分别。在这方面,IL-10,IFN-γ,再刺激后使用ELISA测量IL-4。通过体内肿瘤回归分析评估免疫应答功效。结果显示,与病毒裂解物和肿瘤细胞裂解物的组合相比,用不同滴度的NDV裂解物的免疫显著减少肿瘤体积。此外,与肿瘤细胞裂解液相比,病毒裂解液可以显着提高细胞毒性T淋巴细胞的产生和淋巴细胞的增殖率。此外,我们的主要发现是,瘤周注射的NDV溶胞产物通过增加IL-4,IFN-γ的水平有效地诱导抗肿瘤免疫反应,和IL-10的减少。这些结果表明,这种治疗是一种特殊的,主动免疫机制刺激器,并可能被证明是一种有用的治疗子宫颈癌的治疗方法,值得进一步研究。
    A Newcastle disease virus (NDV) oncolysate has been established as a unique and effective immune-stimulatory root for tumor treatment. Thus, the aim of the current study was to investigate the effects of intratumoral administration of NDV oncolysate on immune response and tumor regression of C57BL/6 mouse model of human papillomavirus (HPV) related transplanted with TC-1 syngeneic cancer cells. To further investigate the mechanism underlying the antitumor response, cytolytic and lymphocyte proliferation responses in splenocytes were measured using lactate dehydrogenase (LDH) release and MTT assays, respectively. In this regard, levels of IL-10, IFN-γ, and IL-4 were measured using ELISA after re-stimulation. The immune responses efficacy was evaluated by in vivo tumor regression assay. The results showed that immunization with the different titers of NDV lysate significantly reduced tumor volume in comparison with a combination of virus lysate and tumor cell lysate. Also, virus lysate could significantly enhance cytotoxic T lymphocyte production and lymphocyte proliferation rates versus tumor cell lysate. Also, our major findings are that the peritumorally injection of NDV oncolysate effectively induces antitumor immune responses through increased levels of IL-4, IFN-γ, and reduction of IL-10. These results indicate that this treatment is a specific, active immune mechanism stimulator, and may prove to be a useful therapeutic for a treatment against cervical cancers and merits further investigation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    Rhabdomyosarcoma (RMS) is the most common pediatric soft-tissue malignant tumor. Treatment of RMS usually includes primary tumor resection along with systemic chemotherapy. Two-dimensional (2D) cell culture systems and animal models have been extensively used for investigating the potential efficacy of new RMS treatments. However, RMS cells behave differently in 2D culture than in vivo, which has recently inspired the adoption of three-dimensional (3D) culture environments. In the current paper, we will describe the detailed methodology we have developed for fabricating a 3D engineered model to study alveolar RMS (ARMS) in vitro. This model consists of a thermally cross-linked collagen disk laden with RMS cells that mimics the structural and bio-chemical aspects of the tumor extracellular matrix (ECM). This process is highly reproducible and produces a 3D engineered model that can be used to analyze the cytotoxicity and autophagy induction of drugs on ARMS cells. The most improtant bullet points are as following:•We fabricated 3D model of ARMS.•The current ARMS 3D model can be used for screening of chemotherapy drugs.•We developed methods to detect apoptosis and autophagy in ARMS 3D model to detect the mechansims of chemotherapy agents.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    克氏锥虫是查加斯病的病原体,影响全球约800万人的感染。寻找新的反T。克鲁兹类药物是相关的,主要是因为这种疾病的治疗仅限于两种药物。这项研究的目的是研究杀锥虫和细胞毒活性,并阐明Lonchocarpuscultrus根提取物的化学特征。从L.cultratus的根被提交到连续提取与己烷,二氯甲烷,和甲醇,导致LCH,LCD,和LCM提取物,分别。使用1H-RMN对提取物进行表征,13C-RMN,CC和TLC。克氏虫形式的治疗(epimastigotes,锥虫,和amastigotes)具有月牙色浓度的LCH,LCD,LCM分别为72、48和48小时,分别。在这之后,计算抑制百分比和IC50/LC50。苯并硝唑用作阳性对照。用不同浓度的两种提取物处理小鼠巨噬细胞48小时,之后,通过MTT法测定细胞活力并计算CC50。在己烷提取物中鉴定出了查耳酮和龙果芸香碱,在Lonchocarpus属中第一次,观察到二氢龙果碱衍生物的存在。在二氯甲烷提取物中检测到其他查耳酮,例如异皮质醇和erioschalconeB。与其他两种提取物相比,二氯甲烷提取物对所有测试形式的克氏毛虫显示出更高的活性,IC50值为10.98、2.42和0.83µg/mL,这些值分别与苯并硝唑的值非常接近。尽管二氯甲烷提取物对哺乳动物细胞具有细胞毒性作用,它显示了对amastigotes的选择性。甲醇提取物显示出最低的抗T。Cruzi活性,但对腹膜鼠巨噬细胞无毒。因此,Lonchocarpus属在过去已经证明了对T.cruzi的epimastigotes形式的作用,但这是第一次显示对感染形式的活性,这导致了进一步的研究与体内测试。
    Trypanosoma cruzi is the agent of Chagas disease, an infection that affects around 8 million people worldwide. The search for new anti-T. cruzi drugs are relevant, mainly because the treatment of this disease is limited to two drugs. The objective of this study was to investigate the trypanocidal and cytotoxic activity and elucidate the chemical profile of extracts from the roots of the Lonchocarpus cultratus. Roots from L. cultratus were submitted to successive extractions with hexane, dichloromethane, and methanol, resulting in LCH, LCD, and LCM extracts, respectively. Characterization of extracts was done using 1H-RMN, 13C-RMN, CC and TLC. Treatment of T. cruzi forms (epimastigotes, trypomastigotes, and amastigotes) with crescent concentrations of LCH, LCD, and LCM was done for 72, 48, and 48 h, respectively. After this, the percentage of inhibition and IC50/LC50 were calculated. Benznidazole was used as a positive control. Murine macrophages were treated with different concentrations of both extracts for 48 h, and after, the cellular viability was determined by the MTT method and CC50 was calculated. The chalcones derricin and lonchocarpine were identified in the hexane extract, and for the first time in the genus Lonchocarpus, the presence of a dihydrolonchocarpine derivative was observed. Other chalcones such as isocordoin and erioschalcone B were detected in the dichloromethane extract. The dichloromethane extract showed higher activity against all tested forms of T. cruzi than the other two extracts, with IC50 values of 10.98, 2.42, and 0.83 µg/mL, respectively; these values are very close to those of benznidazole. Although the dichloromethane extract presented a cytotoxic effect against mammalian cells, it showed selectivity against amastigotes. The methanolic extract showed the lowest anti-T. cruzi activity but was non-toxic to peritoneal murine macrophages. Thus, the genus Lonchocarpus had demonstrated in the past action against epimastigotes forms of T. cruzi but is the first time that the activity against infective forms is showed, which leading to further studies with in vivo tests.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    随着癌细胞增殖并改变其局部环境,与细胞转化相关的遗传改变在很大程度上表达在代谢表型中。并为转移做准备。定性,癌细胞的基本生物化学通常与未转化细胞相同,但是癌细胞会产生局部环境,TME,对基质细胞有敌意,竞争营养。为了扩散,细胞需要充足的营养,要么那些不能由细胞自己制造的,或者必须由更简单的前体制成。然而,在实体瘤中,考虑到快速增殖的潜力,营养供应通常是有限的,和血管质量差。因此,癌细胞可以采用各种策略来获得生存的营养,生长和转移。尽管在标准培养条件下使用已建立的细胞系已经学到了很多东西,从体内代谢研究中可以清楚地看出,这也可能是一种误导,哪种营养素用于能量生产,而不是用于大分子合成的构建模块,甚至在同一个肿瘤内。在这里,我们回顾了代谢网络的运作,以及如何在体内和体外使用稳定的同位素示踪剂揭示TME中营养供应和利用的最新理解。
    The genetic alterations associated with cell transformation are in large measure expressed in the metabolic phenotype as cancer cells proliferate and change their local environment, and prepare for metastasis. Qualitatively, the fundamental biochemistry of cancer cells is generally the same as in the untransformed cells, but the cancer cells produce a local environment, the TME, that is hostile to the stromal cells, and compete for nutrients. In order to proliferate, cells need sufficient nutrients, either those that cannot be made by the cells themselves, or must be made from simpler precursors. However, in solid tumors, the nutrient supply is often limiting given the potential for rapid proliferation, and the poor quality of the vasculature. Thus, cancer cells may employ a variety of strategies to obtain nutrients for survival, growth and metastasis. Although much has been learned using established cell lines in standard culture conditions, it is becoming clear from in vivo metabolic studies that this can also be misleading, and which nutrients are used for energy production versus building blocks for synthesis of macromolecules can vary greatly from tumor to tumor, and even within the same tumor. Here we review the operation of metabolic networks, and how recent understanding of nutrient supply in the TME and utilization are being revealed using stable isotope tracers in vivo as well as in vitro.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:细胞球的形成是生物医学研究中的重要程序。基础研究和治疗应用需要大量均匀尺寸和形状的高质量细胞球。传统方法,包括悬滴法和悬浮培养,用于细胞球生产。然而,这些方法很耗时,细胞球不容易收获,并且很难控制细胞球的大小和几何形状。为了解决这些问题,一种新型的多漏斗细胞培养插入物被设计用于大小控制,容易收获,和扩大细胞球的生产。
    方法:培养基质具有680个微漏斗,顶部宽度为1毫米,0.89mm深度,和0.5毫米见方的底部。小鼠胚胎干细胞用于测试新开发的设备。接种的胚胎干细胞在向下的培养基表面朝向底部开口沉降并聚集为胚状体(EB)。对于细胞球收获,将培养插入物的底部与另一个培养皿中的培养基表面接触,设备中的培养基通过静水压力随细胞球向下流动。
    结果:易于收集具有均匀尺寸和形状的致密细胞球。球体的直径可以通过调节接种细胞密度来控制。与悬浮培养产生的EB相比,使用新插入物产生的EB的自发神经分化(巢蛋白和Tju1)和视黄酸诱导的内胚层分化(Pdx-1和胰岛素I)得到了改善。
    结论:这种新型细胞培养插页将改善细胞球的未来研究,并有利于细胞疗法的临床应用。
    BACKGROUND: Formation of cell spheres is an important procedure in biomedical research. A large number of high-quality cell spheres of uniform size and shape are required for basic studies and therapeutic applications. Conventional approaches, including the hanging drop method and suspension culture, are used for cell sphere production. However, these methods are time consuming, cell spheres cannot be harvested easily, and it is difficult to control the size and geometry of cell spheres. To resolve these problems, a novel multiple-funnel cell culture insert was designed for size controlling, easy harvesting, and scale-up production of cell spheres.
    METHODS: The culture substrate has 680 micro-funnels with a 1-mm width top, 0.89 mm depth, and 0.5 mm square bottom. Mouse embryonic stem cells were used to test the newly developed device. The seeded embryonic stem cells settled at the downward medium surface toward the bottom opening and aggregated as embryoid bodies (EBs). For cell sphere harvest, the bottom of the culture insert was put in contact with the medium surface in another culture dish, and the medium in the device flowed down with cell spheres by hydrostatic pressure.
    RESULTS: Compact cell spheres with uniform size and shape were collected easily. The diameter of the spheres could be controlled by adjusting the seeding cell density. Spontaneous neural differentiation (nestin and Tju1) and retinoic acid-induced endodermal differentiation (Pdx-1 and insulin I) were improved in the EBs produced using the new insert compared to those in EBs produced by suspension culture.
    CONCLUSIONS: This novel cell culture insert shall improve future studies of cell spheres and benefit clinical applications of cell therapy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

       PDF(Pubmed)

  • 文章类型: Journal Article
    某些食物成分具有免疫调节作用。这项研究的目的是阐明甘蓝型油菜的免疫刺激活性的机制。我们证明了口服B.rapaL.的不溶性部分的小鼠的自然杀伤(NK)活性和干扰素(IFN)-γ产生的增强。和NK1.1+细胞是负责产生IFN-γ的主要细胞。此外,结果表明,不溶性部分中的活性化合物被树突状细胞上的Toll样受体(TLR)2,TLR4和C型凝集素受体识别,它们激活了信号级联,如MAPK,NF-κB,还有Syk.这些发现表明,B.rapaL.是一种潜在的有前途的免疫改善材料,它可能有助于通过激活先天免疫来预防免疫疾病,如感染和癌症。
    Certain food components possess immunomodulatory effects. The aim of this study was to elucidate the mechanism of the immunostimulatory activity of Brassica rapa L. We demonstrated an enhancement of natural killer (NK) activity and interferon (IFN)-γ production in mice that were orally administered an insoluble fraction of B. rapa L. The insoluble fraction of B. rapa L. significantly induced IFN-γ production in mouse spleen cells in an interleukin (IL)-12-dependent manner, and NK1.1+ cells were the main cells responsible for producing IFN-γ. Additionally, the results suggested that the active compounds in the insoluble fraction were recognized by Toll-like receptor (TLR) 2, TLR4, and C-type lectin receptors on dendritic cells, and they activated signaling cascades such as MAPK, NF-κB, and Syk. These findings suggest that B. rapa L. is a potentially promising immuno-improving material, and it might be useful for preventing immunological disorders such as infections and cancers by activating innate immunity.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    目的:美沙拉嗪是治疗炎症性肠病(IBD)的一线药物。然而,其机制尚未完全理解。CD4+Foxp3+调节性T细胞(Tregs)在抑制IBD中起潜在作用。这项研究确定了美沙拉嗪的抗炎活性是否与结肠中的Treg诱导有关。
    方法:我们检查了野生型小鼠结肠中Treg的频率,缺乏芳香烃受体的小鼠(AhR-/-小鼠),和造血细胞中缺乏AhR的骨髓嵌合小鼠(BM-AhR-/-小鼠),口服美沙拉嗪治疗后。我们还检查了美沙拉嗪对结肠中转化生长因子(TGF)-β表达的影响。
    结果:用美沙拉嗪处理野生型小鼠增加了Treg在结肠中的积累,并上调了AhR靶基因Cyp1A1,但在AhR-/-或BM-AhR-/-小鼠中未观察到这种作用。此外,美沙拉嗪促进幼稚T细胞体外分化为Tregs,伴随AhR激活。用美沙拉嗪处理的小鼠在结肠中以AhR依赖性方式表现出增加的TGF-β活性形式水平,并且阻断TGF-β信号传导抑制了结肠中美沙拉嗪对Treg的诱导。此外,用美沙拉嗪预处理的小鼠获得了对葡聚糖硫酸钠诱导的结肠炎的抗性。
    结论:我们提出了一种新的美沙拉嗪治疗结肠炎的抗炎机制:通过AhR途径在结肠中诱导Tregs,随后是TGF-β激活。
    OBJECTIVE: Mesalamine is a first-line drug for treatment of inflammatory bowel diseases (IBD). However, its mechanisms are not fully understood. CD4+ Foxp3+ regulatory T cells (Tregs) play a potential role in suppressing IBD. This study determined whether the anti-inflammatory activity of mesalamine is related to Treg induction in the colon.
    METHODS: We examined the frequencies of Tregs in the colons of wild-type mice, mice deficient for aryl hydrocarbon receptor (AhR-/- mice), and bone marrow-chimeric mice lacking AhR in hematopoietic cells (BM-AhR-/- mice), following oral treatment with mesalamine. We also examined the effects of mesalamine on transforming growth factor (TGF)-β expression in the colon.
    RESULTS: Treatment of wild-type mice with mesalamine increased the accumulation of Tregs in the colon and up-regulated the AhR target gene Cyp1A1, but this effect was not observed in AhR-/- or BM-AhR-/- mice. In addition, mesalamine promoted in vitro differentiation of naive T cells to Tregs, concomitant with AhR activation. Mice treated with mesalamine exhibited increased levels of the active form of TGF-β in the colon in an AhR-dependent manner and blockade of TGF-β signaling suppressed induction of Tregs by mesalamine in the colon. Furthermore, mice pretreated with mesalamine acquired resistance to dextran sodium sulfate-induced colitis.
    CONCLUSIONS: We propose a novel anti-inflammatory mechanism of mesalamine for colitis: induction of Tregs in the colon via the AhR pathway, followed by TGF-β activation.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

  • 文章类型: Journal Article
    在3%-5%的非小细胞肺癌(NSCLC)中观察到间变性淋巴瘤激酶(ALK)融合癌基因。克唑替尼和色瑞替尼,下一代ALK酪氨酸激酶抑制剂(TKI)对克唑替尼难治性患者有效,临床上可用于ALK重排的NSCLC患者的治疗,和多个下一代ALK-TKIs目前正在临床评估中。这些ALK-TKIs在ALK重排的NSCLC患者中表现出强大的临床活性;然而,ALK-TKI耐药的出现限制了治疗效果。迄今为止,已鉴定出各种次级突变或旁路途径激活介导的抗性,但是抵抗机制的很大一部分尚未确定。这里,我们报道了在ALK重排的NSCLC患者中发现P-糖蛋白(P-gp/ABCB1)过表达是一种ceritinib耐药机制.P-gp出口色瑞替尼,其过度表达赋予色瑞替尼和克唑替尼耐药,但不是PF-06463922或alectinib,是下一代ALK抑制剂。敲除ABCB1或P-gp抑制剂可使患者来源的癌细胞对ceritinib敏感,在体外和体内。在ALK重排的克唑替尼或色瑞替尼耐药的NSCLC患者中,11例中有3例发现P-gp过表达。我们的研究表明,阿列替尼,PF-06463922或P-gp抑制剂与色瑞替尼可以克服由P-gp过表达介导的色瑞替尼或克唑替尼耐药性。
    The anaplastic lymphoma kinase (ALK) fusion oncogene is observed in 3%-5% of non-small cell lung cancer (NSCLC). Crizotinib and ceritinib, a next-generation ALK tyrosine kinase inhibitor (TKI) active against crizotinib-refractory patients, are clinically available for the treatment of ALK-rearranged NSCLC patients, and multiple next-generation ALK-TKIs are currently under clinical evaluation. These ALK-TKIs exhibit robust clinical activity in ALK-rearranged NSCLC patients; however, the emergence of ALK-TKI resistance restricts the therapeutic effect. To date, various secondary mutations or bypass pathway activation-mediated resistance have been identified, but large parts of the resistance mechanism are yet to be identified. Here, we report the discovery of p-glycoprotein (P-gp/ABCB1) overexpression as a ceritinib resistance mechanism in ALK-rearranged NSCLC patients. P-gp exported ceritinib and its overexpression conferred ceritinib and crizotinib resistance, but not to PF-06463922 or alectinib, which are next-generation ALK inhibitors. Knockdown of ABCB1 or P-gp inhibitors sensitizes the patient-derived cancer cells to ceritinib, in vitro and in vivo. P-gp overexpression was identified in three out of 11 cases with in ALK-rearranged crizotinib or ceritinib resistant NSCLC patients. Our study suggests that alectinib, PF-06463922, or P-gp inhibitor with ceritinib could overcome the ceritinib or crizotinib resistance mediated by P-gp overexpression.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Sci-hub)

公众号